Switch of anti-VEGF agents (Bevacizumab and Ranibizumab) in non-responders to anti-VEGF treatment in AMD
- Conditions
- H35.3Degeneration of macula and posterior pole
- Registration Number
- DRKS00004918
- Lead Sponsor
- niversitäts-Augenklinik Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 435
Inclusion Criteria
intravitreal injections for treatment of AMD, switch of medication after at least 3 monthly injections to the other medication after max. 100 days, at least 3 monthly injections after switch, data available for visual acuity before,a fter, and at time of switch
Exclusion Criteria
indications other than AMD, other reasons/comorbidity for impaired visual acuity, intraocular surgery during time of study, therapy regime other than mentioned under inclusion criteria, macular hemorrhage during time of study, missing data
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method